Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer
/
Date26 Sep 2016
PALO ALTO, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) — Orbus Therapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development and commercialization of therapies... Read More →
uniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City
/
Date26 Sep 2016
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Sept. 26, 2016 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that... Read More →
LILLY MARKS NAMED BOARD CHAIR OF THE ASSOCIATION OF ACADEMIC HEALTH CENTERS
/
Date26 Sep 2016
WASHINGTON, Sept. 26, 2016 (GLOBE NEWSWIRE) — Lilly Marks, vice President for health affairs for the University of Colorado and Anschutz Medical Campus, was named... Read More →
LILLY MARKS NAMED BOARD CHAIR OF THE ASSOCIATION OF ACADEMIC HEALTH CENTERS
/
Date26 Sep 2016
WASHINGTON, Sept. 26, 2016 (GLOBE NEWSWIRE) — Lilly Marks, vice President for health affairs for the University of Colorado and Anschutz Medical Campus, was named... Read More →
The 1st Presidential Debate: Understanding Social Security, Medicare, Unemployment Insurance, and Workers' Compensation
/
Date26 Sep 2016
WASHINGTON, Sept. 26, 2016 (GLOBE NEWSWIRE) — What: Our nation’s social insurance programs provide fundamental economic security to millions of working Americans and their families.... Read More →
Global Public Cloud Platform as a Service (PaaS) Market worth USD 9.12 billion by 2021 – Zion Market Research
/
Date26 Sep 2016
Sarasota, FL, Sept. 26, 2016 (GLOBE NEWSWIRE) — Zion Market Research has published a new report titled “Public Cloud Platform as a Service (PaaS) Market... Read More →
Preliminary clinical results for Entia Biosciences, Inc.’s new, proprietary ErgoD2® medical food show an average increase in kidney filtration rate of approximately 10% for over 75% of test subjects, after only three months
/
Date26 Sep 2016
PORTLAND, Ore., Sept. 26, 2016 (GLOBE NEWSWIRE) — Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported better-than-expected... Read More →
Minerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs
/
Date26 Sep 2016
Last patient completes extension phase of Phase IIb trial with MIN-101 Company receives FDA acceptance of Investigational New Drug Application for MIN-117 WALTHAM, Mass., Sept.... Read More →
Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy
/
Date26 Sep 2016
Once-daily dose identified for the pivotal Phase 3 study Well tolerated with no drug-related severe or serious adverse events reported SALT LAKE CITY, Sept. 26,... Read More →
Complete Response Letter for REMOXY®
/
Date26 Sep 2016
AUSTIN, Texas, Sept. 26, 2016 (GLOBE NEWSWIRE) — Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that it has received a Complete Response Letter (CRL) from the... Read More →